Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|24|1|77-84

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.24, Iss.1, 2018-01, pp. : 77-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 6, 2015-06 ,pp. : 967-977

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 162-170

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factor viii assays in haemophilia a patients treated with refacto™

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 121, Iss. 2, 2003-04 ,pp. : 379-380

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant Factor VII (Activated) for Haemorrhagic Complications of Severe Sepsis Treated with Recombinant Protein C (Activated)

By  

Acta Haematologica, Vol. 116, Iss. 2, 2006-08 ,pp. : 126-130

Karger

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite